141 acres land allocated to set up Pharma park in Naya Raipur

Raipur:  Chhattisgarh is positioning itself as a new pharmaceutical centre in central India, with the Naya Raipur Atal Nagar Development Authority allocating 141.84 acres in Sector-22 to foster research, development, and international investment in pharmaceuticals. The Chhattisgarh State Industrial Development Corporation (CSIDC) received this land allocation for establishing a pharmaceutical park.
The state govt’s representative emphasises that developing Chhattisgarh requires strengthening and making healthcare services more accessible to citizens. The pharmaceutical park initiative aligns with this goal, supported by the new industrial policy 2024-30, which offers various facilities and concessions to pharmaceutical industries.

The administration anticipates that this project will draw both domestic and international investments, foster competition in the pharmaceutical sector, create employment for local youth, and enhance the state’s economic growth.

“With the establishment of the pharmaceutical park, we will be able to easily meet the growing demand for healthcare products at the domestic and global levels. Through Chhattisgarh’s Shaheed Veer Narayan Singh Ayushman Health Scheme, 77.20 lakh families in the state are getting free treatment up to Rs 5 lakh, which is aimed to be increased to Rs 10 lakh in the coming times,” stated the govt spokesperson.

The facility will provide comprehensive support for pharmaceutical units specialising in Ayush products, featuring modern infrastructure including a flatted factory complex and a common effluent treatment plant (CETP). The park will also house research and development centres and testing laboratories.
The state govt offers 100% industrial investment promotion on capital investments for large-scale pharmaceutical enterprises. Units receive reimbursement of up to 100% of net SGST paid for 12 years from the start of commercial production or a capital investment grant.

The administration provides grants of Rs 60 crore for investments between Rs 50-200 crore, Rs 150 crore for investments between Rs 200-500 crore, and Rs 300 crore for investments exceeding Rs 500 crore. Additional benefits under the new industrial policy include a 12-year electricity charge exemption, stamp duty waiver, and 50% reimbursement on registration fees and new electricity connection charges.

Related Posts

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

New Delhi: AstraZeneca’s India-arm has partnered with National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, to build clinical research capabilities at 25 emerging geographies in a bid to extend…

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into papillary-only non-muscle-invasive bladder cancer (NMIBC). Wednesday’s approval comes nearly three months ahead…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction